Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections
Information source: Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes Mellitus; Diabetic Foot
Intervention: Piperacillin/Tazobactam (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Wyeth is now a wholly owned subsidiary of Pfizer Official(s) and/or principal investigator(s):
Medical Monitor, MD, Study Director, Affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
Summary
Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy
and Safety data in Diabetic Inpatients.
Clinical Details
Official title: An Open-label, Randomized Study Comparing the Efficacy and Safety of Piperacillin/Tazobactam and Ampicillin/Sulbactam Administered Intravenously in the Empirical Treatment of Foot Infections in Diabetic Inpatients
Study design: Masking: Open Label, Primary Purpose: Treatment
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria
- Patients with diabetes mellitus
- Inpatient
- Have 1 or more infected ulcer(s) below the ankle
Exclusion Criteria
- Must not have gangrene or severely impaired arterial supply in your foot
- Must not have a bone infection in the area of your ulcer
- Must not have allergies to penicillins
Locations and Contacts
Additional Information
Starting date: October 2000
Last updated: February 7, 2013
|
